Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

6.3K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.3K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

2.9K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K
Diabetic Retinopathy01:27

Diabetic Retinopathy

48
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
48
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.0K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.6K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.6K
Gene Therapy00:59

Gene Therapy

22.1K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
22.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genotype-Phenotype Correlations in RPGRIP1-Associated Retinal Dystrophy in a Nationwide Japanese Cohort.

American journal of ophthalmology·2026
Same author

Molecular and clinical features of a Japanese medulloblastoma cohort: Subgroup-specific prognostic stratification using economical/accessible diagnostic methods.

Brain pathology (Zurich, Switzerland)·2026
Same author

Gel Immersion vs. Water Immersion Endoscopic Ultrasound for Visualization of the Duodenal Papilla and Periampullary Lesions: A Dual-Center Retrospective Study With Blinded Evaluation of Archived Videos.

Journal of hepato-biliary-pancreatic sciences·2026
Same author

Nutritional intake and growth in children with intestinal failure: An exploratory cross-sectional study.

Intestinal Failure (New York, N.Y.)·2026
Same author

Foramen Magnum Stenosis in Achondroplasia: Imaging-Based Surgical Indications, Synchondrosis Fusion, and the Role of Ventriculomegaly.

Pediatric neurosurgery·2026
Same author

Migration of Fish Bones to the Bile Duct Following Hepaticojejunostomy.

DEN open·2026

Related Experiment Video

Updated: Apr 26, 2026

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
07:04

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

2.0K

Genistein attenuates choroidal neovascularization.

Satoshi Kinoshita1, Kousuke Noda1, Yoshiaki Tagawa1

  • 1Laboratory of Ocular Cell Biology and Visual Science; Department of Ophthalmology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.

The Journal of Nutritional Biochemistry
|August 13, 2014
PubMed
Summary

Genistein, a soy flavonoid, significantly reduced choroidal neovascularization (CNV) in mice. It also decreased key inflammatory markers, indicating its anti-angiogenic potential for eye conditions.

Keywords:
Age-related macular DegenerationChoroidal neovascularizationFlavonoidGenisteinMatrix metalloproteinase-9

More Related Videos

A Mouse Model for Laser-induced Choroidal Neovascularization
07:08

A Mouse Model for Laser-induced Choroidal Neovascularization

Published on: December 27, 2015

18.2K
The Corneal Micropocket Assay: A Model of Angiogenesis in the Mouse Eye
11:49

The Corneal Micropocket Assay: A Model of Angiogenesis in the Mouse Eye

Published on: August 16, 2014

16.5K

Related Experiment Videos

Last Updated: Apr 26, 2026

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
07:04

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

2.0K
A Mouse Model for Laser-induced Choroidal Neovascularization
07:08

A Mouse Model for Laser-induced Choroidal Neovascularization

Published on: December 27, 2015

18.2K
The Corneal Micropocket Assay: A Model of Angiogenesis in the Mouse Eye
11:49

The Corneal Micropocket Assay: A Model of Angiogenesis in the Mouse Eye

Published on: August 16, 2014

16.5K

Area of Science:

  • Ophthalmology
  • Molecular Biology
  • Pharmacology

Background:

  • Genistein is a soy-derived flavonoid with known anti-inflammatory and anti-angiogenic properties.
  • Intraocular neovascularization, such as choroidal neovascularization (CNV), is a significant cause of vision loss.
  • Investigating dietary compounds for therapeutic potential in ocular diseases is crucial.

Purpose of the Study:

  • To evaluate the efficacy of genistein in inhibiting laser-induced choroidal neovascularization (CNV) in a mouse model.
  • To determine the molecular mechanisms underlying genistein's effects on CNV formation.

Main Methods:

  • A laser-induced CNV model was established in C57BL/6J mice.
  • Mice were fed a diet containing 0.5% genistein or a control diet.
  • CNV lesion size was quantified, and levels of MCP-1, ICAM-1, MMP-9, Ets-1, and F4/80 were measured.

Main Results:

  • Genistein treatment significantly reduced the size of CNV lesions compared to controls.
  • Genistein significantly decreased the protein levels of monocyte chemoattractant protein-1 (MCP-1), intercellular adhesion molecule-1 (ICAM-1), and matrix metalloproteinase-9 (MMP-9).
  • Genistein suppressed the expression of Ets-1 and F4/80 in the retinal pigment epithelium-choroid complex.

Conclusions:

  • Genistein exhibits significant anti-angiogenic effects in the context of choroidal neovascularization.
  • Genistein's mechanism involves the downregulation of key inflammatory and angiogenic factors.
  • These findings suggest genistein as a potential therapeutic agent for treating neovascular eye diseases.